BioStock: Spago Nanomedical publishes positive preclinical data

Preclinical data with Spago Nanomedical’s radionuclide therapy concept Tumorad was recently published in the scientific journal ACS Omega. The paper describes the composition, stability and mode of action for the drug candidate ¹⁷⁷Lu-SN201 and concludes that the candidate’s properties are suitable for systemic treatment of cancer. BioStock reached out to CEO Mats Hansen to learn more on what this means for the project.

Read the full interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2023/01/spago-nanomedical-publishes-positive-preclinical-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/